Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial
- PMID: 16413875
- DOI: 10.1016/S0140-6736(05)67861-0
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial
Abstract
Background: The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by post-infarction left-ventricular (LV) dysfunction. Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure.
Methods: We did a randomised, double-blind, placebo-controlled study in 67 patients from whom we harvested bone marrow 1 day after successful percutaneous coronary intervention for STEMI. We assigned patients optimum medical treatment and infusion of placebo (n=34) or BMSC (n=33). Our primary endpoint was the increase in LV ejection fraction and our secondary endpoints were change in infarct size and regional LV function at 4 months' follow-up, all assessed by MRI. We assessed changes in myocardial perfusion and oxidative metabolism with serial 1-[11C]acetate PET. Analyses were per protocol. This study is registered with , number NCT00264316.
Findings: Mean global LV ejection fraction 4 days after percutaneous coronary intervention was 46.9% (SD 8.2) in controls and 48.5% (7.2) in BMSC patients, and increased after 4 months to 49.1% (10.7) and 51.8% (8.8; OR for treatment effect 1.036, 95% CI 0.961-1.118, p=0.36). Compared with placebo infusion, BMSC transfer was associated with a significant reduction in myocardial infarct size (BMSC treatment effect 28%, p=0.036) and a better recovery of regional systolic function. Myocardial perfusion and metabolism increased similarly in both groups. We noted no complications associated with BMSC transfer and all but one patient in the BMSC group completed the 4 months' follow-up.
Interpretation: Intracoronary transfer of autologous bone marrow cells within 24 h of optimum reperfusion therapy does not augment recovery of global LV function after myocardial infarction, but could favourably affect infarct remodelling.
Comment in
-
Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk.Lancet. 2006 Jan 14;367(9505):87-8. doi: 10.1016/S0140-6736(05)67895-6. Lancet. 2006. PMID: 16413856 No abstract available.
-
Autologous bone-marrow stem cells for myocardial infarction.Lancet. 2006 Jul 1;368(9529):27. doi: 10.1016/S0140-6736(06)68963-0. Lancet. 2006. PMID: 16815373 No abstract available.
Similar articles
-
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.Lancet. 2004 Jul 10-16;364(9429):141-8. doi: 10.1016/S0140-6736(04)16626-9. Lancet. 2004. PMID: 15246726 Clinical Trial.
-
Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction.Am J Cardiol. 2009 Nov 15;104(10):1336-42. doi: 10.1016/j.amjcard.2009.06.057. Epub 2009 Sep 25. Am J Cardiol. 2009. PMID: 19892047 Clinical Trial.
-
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.Circulation. 2006 Mar 14;113(10):1287-94. doi: 10.1161/CIRCULATIONAHA.105.575118. Epub 2006 Mar 6. Circulation. 2006. PMID: 16520413 Clinical Trial.
-
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.Am Heart J. 2011 Oct;162(4):671-7. doi: 10.1016/j.ahj.2011.06.019. Am Heart J. 2011. PMID: 21982659 Review.
-
Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.Eur Heart J. 2014 Apr;35(15):989-98. doi: 10.1093/eurheartj/eht372. Epub 2013 Sep 11. Eur Heart J. 2014. PMID: 24026778 Free PMC article. Review.
Cited by
-
Cell-Based Therapies for Heart Failure.Front Pharmacol. 2021 Apr 12;12:641116. doi: 10.3389/fphar.2021.641116. eCollection 2021. Front Pharmacol. 2021. PMID: 33912054 Free PMC article.
-
Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy.Stem Cells Transl Med. 2012 Jan;1(1):29-35. doi: 10.5966/sctm.2011-0014. Epub 2011 Dec 7. Stem Cells Transl Med. 2012. PMID: 23197637 Free PMC article. Review.
-
Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome?EPMA J. 2011 Mar;2(1):107-17. doi: 10.1007/s13167-011-0062-5. Epub 2011 Feb 8. EPMA J. 2011. PMID: 23199132 Free PMC article.
-
CMR of microvascular obstruction and hemorrhage in myocardial infarction.J Cardiovasc Magn Reson. 2012 Sep 29;14(1):68. doi: 10.1186/1532-429X-14-68. J Cardiovasc Magn Reson. 2012. PMID: 23021401 Free PMC article. Review.
-
Rejuvenation: an integrated approach to regenerative medicine.Regen Med Res. 2013 Dec 2;1(1):7. doi: 10.1186/2050-490X-1-7. eCollection 2013 Dec. Regen Med Res. 2013. PMID: 25984326 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical